在低密度脂蛋白受体缺乏小鼠的内毒素和饮食诱导的动脉样硬化中,替代性途径对致病补体激活至关重要
Talat H Malik1, Andrea Cortini, Daniele Carassiti
1Rheumatology Section, Division of Immunology and Inflammation, Department of Medicine, Imperial College, London, UK.
Circulation
|October 27, 2010
概括
替代补充途径驱动动动脉硬化,特别是在对内毒素和高脂肪饮食的反应中. 阻止这种途径可以减少小鼠的动脉样硬化斑块的发展.
科学领域:
- 免疫学 免疫学 免疫学
- 心血管科学 心血管科学
- 补充系统生物学 补充系统生物学
背景情况:
- 经典和莱克补充通路在低密度脂蛋白受体缺乏 (Ldlr(-/-)) 的小鼠中预防早期动脉样硬化.
- 替代补充途径在动脉动脉生成中的特定作用以前是未知的.
研究的目的:
- 调查替代补充途径在动脉形成中的作用.
- 确定是否需要替代途径用于内毒素介导或饮食诱导的动脉样硬化.
主要方法:
- 缺乏低密度脂蛋白受体 (Ldlr(-/-)) 的小鼠与缺乏B因子 (Bf(-/-) 的小鼠交叉,这是替代途径启动者.
- 小鼠接受了益风性病原性条件,包括低脂肪饮食,脂多糖类药物和高脂肪饮食.
- 评估了动脉样硬化发展,脂质概况和补充激活.
主要成果:
- 缺乏B因子 (Bf(-/-) /Ldlr(-/-)) 的小鼠在低脂肪饮食下与Ldlr(-/-) 的小鼠相比,在动脉样硬化方面没有差异.
- 在Bf(-/-) /Ldlr(-/-) 小鼠中,脂多糖胺诱导的动脉样硬化显著降低,这表明替代途径对内毒素介导的动脉样发生有必要.
- 高脂肪饮食导致Bf(-/-) /Ldlr(-/-) 小鼠的病变面积和复杂性减少,伴随着补体激活的减少.
结论:
- 替代补充通路,当被脂多糖或高脂肪饮食激活时,会促进动脉样硬化.
- 阻断替代途径减少了动脉样硬化斑块的发展和复杂性在Ldlr-/-) 小鼠.
相关概念视频
Receptor-mediated Endocytosis
113.8K
Overview
113.8K
Inflammation
65.3K
Overview
65.3K
Complement System
12.9K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
12.9K
Coronary Artery Disease II: Pathophysiology
1.0K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.0K
Atherosclerosis I: Introduction
2.1K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.1K
Atherosclerosis III: Management
603
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
603


